Navigation Links
FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
Date:5/12/2008

ST. DAVID'S, Bermuda and COPENHAGEN, Denmark, May 12 /PRNewswire-FirstCall/ -- Warner Chilcott and LEO Pharma announced today that the United States Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Taclonex Scalp(R) (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension. LEO Pharma submitted the NDA for Taclonex Scalp(R) to the FDA in July 2007. Taclonex Scalp(R) is a topical suspension containing a combination of calcipotriene 0.005% and betamethasone dipropionate 0.064% for the treatment of moderate to severe psoriasis vulgaris of the scalp in adults. Taclonex Scalp(R) is called Xamiol(R) outside the United States.

"Taclonex Scalp(R) represents an exciting addition to our Taclonex(R) and Dovonex(R) franchise, expanding the treatment options for psoriasis patients in the U.S.," said Roger Boissonneault, CEO of Warner Chilcott Limited.

Warner Chilcott is LEO Pharma's exclusive licensee of Taclonex(R) and Dovonex(R) products in the United States. Warner Chilcott expects to launch Taclonex Scalp(R) in the second half of 2008. As a result of the FDA approval of Taclonex Scalp(R), Warner Chilcott will pay a milestone payment of $40 million to LEO Pharma in June 2008. Warner Chilcott will record the milestone payment as an intangible asset on its balance sheet and will amortize it over the useful life of the product.

Psoriasis is a chronic, inflammatory skin disease for which there is no cure. In plaque psoriasis (psoriasis vulgaris), the most common type, patches of skin called "lesions" become inflamed and are covered by silvery white scales. A non-contagious disorder, psoriasis can occur on any part of the body, and can significantly alter a sufferer's life both physically and mentally, including the ability to work, play and interact with others. Scalp psoriasis is very common. In fact, at least half of all people who have psoriasis have it on their scalp. As with psoriasis elsewhe
'/>"/>

SOURCE Warner Chilcott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. FDA Approves Health Claim for Brown Rice
2. FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents
3. FDA approves HeartMate II mechanical heart pump for heart-failure patients
4. FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
5. FDA Approves New Once-a-Month Dose of Actonel for Postmenopausal Osteoporosis
6. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
7. FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE
8. House Overwhelmingly Approves Renewal and Tripling of Successful U.S. Global AIDS Prevention Effort
9. VeriPrime Approves New Best Practices for Beef Production
10. U.S. EPA Approves Registration of Antimicrobial Copper Alloys
11. Arizona Senate Approves Smoking Cessation Treatments for State Medicaid Beneficiaries

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... Nov. 27 Preventing dis... fortunately every year, new vaccines are being ad...ccines boost immunity for the same period of time?...needed to keep immunity strong? ,, In this mo...ican Academy of Pediatrics, Michael Pichichero MD,...
(Date:11/27/2009)...-emission vehicles may reduce future disease burde...HealthDay News) -- Encouraging city dwellers to wa...uch greater public health benefits than increased ...ve found. , The study compared the projected he...nsport scenarios for London, England, and Delhi, I...
(Date:11/27/2009)...lti-purpose bilingual coloring books designed for ...iness community to educate - inform parents and ch...issues to Dinosuars to ABC,S and a host of other t...(PRWEB) November 27, 2009 -- Today’s childre... them busy any hour of the day, but one of the old...
(Date:11/26/2009)...., Nov. 27 The diabetes population...next 25 years and annual medical spending on the d...113 billion today, according to a study published ...ional Changing Diabetes ® Program (NCDP), a ... by a team from the University of Chicago. ,, A...
(Date:11/26/2009)...n on an emotional rollercoaster, study finds , ...l it the fear factor meets the jubilant sports fan...ecially those who root for the winning team -- enj...tested match and victory was in doubt, producing f...at this Thanksgiving weekend as you,re glued to th...
Breaking Medicine News(10 mins):Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3
...eilman Center,electro-mechanical manufacturing pla... a 2007 IndustryWeek magazine "Best Plant Finalist...e on the leading edge of efforts to,increase compe...09/MEDRADLOGO ) MEDRAD,s Heilman Center plant wa...
... patients, side effects impacting cognition don,t ...ng to a new survey, the cognitive impairment exper...be long-lasting and severely affect their personal...nize or multi-task have led to significant problem...
...7 The first significant genetic finding in premen...rted. PMDD is a very severe form of the more comm... heritable, affects 5-8% of women, and is associat... that quality of life is seriously impacted. Prev...
...Sales of World,s First Pocket Ultrasound ...if., Oct. 2 Siemens Medical,Solutions (http://ww...of medicine,with today,s launch of the world,s sma...1.6 pounds, and fits easily,into a lab coat pocket...
...imax GmbH, Campbell,CA, is pleased to announce tha...nc. the company is moving to larger premises in No...d. As of October 1st, 2007,joimax, Inc. will be lo...Michael Stek, CEO of the joimax, Inc. "Due to the ...
... Phylonix Pharmaceuticals, Inc. today announced t...l Business Innovation Grant (SBIR) from the Nation...lth (NIH) to develop zebrafish eye disease models ...onserved organ and the basic structure between hum...
Other Medicine News:Health News:MEDRAD Plant Named IndustryWeek Magazine Award Finalist 2Health News:MEDRAD Plant Named IndustryWeek Magazine Award Finalist 3Health News:Cognitive deficits lead to 'loss of self' among cancer patients 2Health News:First significant genetic finding in severe PMS, or PMDD 2Health News:Good Imaging Now Comes in the World's Smallest Ultrasound Package 2Health News:Good Imaging Now Comes in the World's Smallest Ultrasound Package 3Health News:NIH awards Phylonix phase II SBIR to develop zebrafish models for eye diseases 2
(Date:11/25/2009)..., WESTON, Fla., Nov. 25 /PRNewswire-FirstCall/ -... ASFX) ("the Company") is pleased to announce that...ion management office in Shanghai, China. ,, AS...ding an essential gateway for the development and ... products for children and adults to be distribute...
(Date:11/25/2009)...RINCETON, N.J., Nov. 25 ...e pharmaceutical company committed to discovering,...at viral infections, reported financial results fo...tember 30, 2009 Pharmasset held $58.4 million in c... ,, Pipeline Update and 2009 Highlights ,,...
(Date:11/25/2009)...XTON, Pa., Nov. 25 BioTrends Resea...nds(TM) : Stelara report, the first in a mult...g the launch of Centocor Ortho-Biotech,s Stelara, ...f availability. Each wave of the report provides ...ists and qualitative information from a subset of ...
Breaking Medicine Technology:American Scientific Resources Inc. Opens Shanghai Location 2Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Iowa Drug Card a Huge Success With Iowans 55345 1Iowa Drug Card a Huge Success With Iowans 55345 2VA Chiefs Vow to The American Legion 3A We Will End Vet Homelessness 55343 1VA Chiefs Vow to The American Legion 3A We Will End Vet Homelessness 55343 2Mayo Clinic Proceedings 3A Common Blood Disorder May Not be Linked to as Many Serious Diseases as Previously Thought 55341 1Mayo Clinic Proceedings 3A Common Blood Disorder May Not be Linked to as Many Serious Diseases as Previously Thought 55341 2Mayo Clinic Proceedings 3A Common Blood Disorder May Not be Linked to as Many Serious Diseases as Previously Thought 55341 3
... out of ten patients taking,once-daily Lialda rema...TON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- ...nsion study (303),presented at the British Society...tland in March 2007 showed Shire plc,s,Lialda(mesa...atients. Today, secondary endpoints of study 303 w...
...tion in Risk of Hospitalization,from Crohn,s Disea... 22, 2007 /PRNewswire-FirstCall/ -- Abbott,today a...otal study,presented at the Digestive Disease Week...ts with moderate to severely active,Crohn,s diseas...therapy were almost 60 percent less likely than pa...
Other Medicine Technology:Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 2Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 4Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 5Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 7Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 8New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 2New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 3New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 4New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 5New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 6New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 7
Rheumatoid Factor Control
Microalbumin Urine Control
...he K-ASSAY Liquid Lipid Control is intended for us...sample of known concentration for monitoring assay...K-ASSAY Liquid Lipid Control with patient serum sp...tuents. The user can compare observations with exp...
Lyophilized ITA Control for K - ASSAY® Reagents
Medicine Products: